Gordon R Mills

US Patent:

6355618, Mar 12, 2002

Filed:

Apr 7, 2000

Appl. No.:

09/545565

Inventors:

Sui Xiong Cai - San Diego CA
Eckard Weber - San Diego CA
Yan Wang - San Diego CA
Gordon B. Mills - Houston TX
Douglas R. Green - San Diego CA

Assignee:

Cytovia, Inc. - Irvine CA

International Classification:

A61K 3805

US Classification:

514 19, 546335, 549287, 549405, 560 38, 560 39, 560125, 560169, 560170, 562450, 562507, 562561, 562564, 5142375, 514357, 514456, 514478, 514557, 514563

Abstract:

The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R -R , X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

US Patent:

6495522, Dec 17, 2002

Filed:

Aug 28, 2000

Appl. No.:

09/649810

Inventors:

Yan Wang - San Diego CA
Sui Xiong Cai - San Diego CA
Eckard Weber - San Diego CA
Gordon B. Mills - Houston TX
Douglas R. Green - San Diego CA
Lufeng Guan - San Diego CA

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 31195

US Classification:

514 19, 435 11, 435 2, 435260, 435405, 504115, 514183, 514399, 514478, 514534, 514538, 514563, 558275, 558276, 560 37, 560 51, 560129, 560169, 560170, 562442, 562553, 562561, 562569, 5483341

Abstract:

The present invention is directed to novel substituted -hydroxy acid thereof, represented by the general Formula I: where R -R , X and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

US Patent:

6566338, May 20, 2003

Filed:

Oct 11, 2000

Appl. No.:

09/685689

Inventors:

Eckard Weber - San Diego CA
Gordon B. Mills - Houston TX
Douglas R. Green - San Diego CA

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 3805

US Classification:

514 19, 514 18, 514 2, 436 86, 436 90, 435219, 435366, 435404, 2609982

Abstract:

The use of caspase inhibitors for treating, ameliorating, and preventing non-cancer cell death during chemotherapy and radiation therapy and for treating and ameliorating the side effects of chemotherapy and radiation therapy of cancer is disclosed.

US Patent:

6716818, Apr 6, 2004

Filed:

Nov 14, 2001

Appl. No.:

09/987417

Inventors:

Sui Xiong Cai - San Diego CA
Eckard Weber - San Diego CA
Yan Wang - San Diego CA
Gordon B Mills - Houston TX
Douglas R Green - San Diego CA

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 3806

US Classification:

514 19, 514456, 514357, 5143715, 514 18, 514 2, 514478, 514546, 514557, 514563

Abstract:

The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R -R , X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

US Patent:

7074911, Jul 11, 2006

Filed:

Sep 24, 2003

Appl. No.:

10/670135

Inventors:

Gordon B. Mills - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 15/57
C12N 9/64
C12N 15/79

US Classification:

536 232, 435 691, 4352523, 4353201

Abstract:

The instant invention relates to the determination that constitutively nearly silent GrB locus in human breast carcinoma and osteosarcoma cells activated upon retinoblastoma protein (pRB)-induced growth arrest owing to the usage of an alternative promoter/transcription start site. Cloned novel cDNA from the locus adds 34 amino acid residues to the N-terminus of GrB zymogen. The alternate product has been designated as GrB-NIC. Tumor cells with accumulated endogenous GrB-NIC, whose mature form was identical to lymphocyte GrB but with a distinctive glycosylation pattern, undergoes post-growth-arrest apoptosis that occurs concurrently with pRB cleavage, and are capable of inducing rapid apoptosis of bystander pRB tumor cells. Expression of GrB-NIC is also observed in malignant cells of other types as well as in normal non-immune cells upon cell differentiation, especially in differentiating and differentiated neural cells. GrB-NIC plays a physiological role in embryonic, and particularly in early neuronal development.

US Patent:

7470509, Dec 30, 2008

Filed:

Feb 7, 2003

Appl. No.:

10/361112

Inventors:

Andrew I. Damokosh - West Hartford CT, US
Natalia Iartchouk - Wayland MA, US
Edwin A. Clark - Pennington NJ, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 1/68

US Classification:

435 6, 536 231, 536 235, 435 4

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

US Patent:

7494775, Feb 24, 2009

Filed:

Mar 11, 2005

Appl. No.:

11/080991

Inventors:

Ole Petter Veiby - Westborough MA, US
Gordon B. Mills - Houston TX, US
Gabriel N. Hortobagyi - Bellaire TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
UT Board of Regents - Austin TX

International Classification:

C12Q 1/68

US Classification:

435 6, 435 911, 536 231

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.

US Patent:

7670767, Mar 2, 2010

Filed:

Aug 4, 1997

Appl. No.:

08/905508

Inventors:

Laleh Shayesteh - Foster City CA, US
Joe W. Gray - San Francisco CA, US
Gordon B. Mills - Houston TX, US
Yiling Lu - Houston TX, US

Assignee:

The Regents of the University of California - Oakland CA
Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68

US Classification:

435 6, 514 2

Abstract:

The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.